Skip to main content
Mark Lebwohl, MD, Dermatology, New York, NY

MarkGabrielLebwohlMD

Dermatology New York, NY

Dean for Clinical Therapeutics, Professor and Chairman Emeritus of Dermatology, Icahn School of Medicine at Mount Sinai

Overview of Dr. Lebwohl

Dr. Mark Lebwohl is a dermatologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, New York Eye and Ear Infirmary of Mount Sinai, and Mount Sinai Brooklyn. He received his medical degree from Harvard Medical School and has been in practice 45 years. He is one of 53 doctors at Mount Sinai Brooklyn and one of 26 doctors at New York Eye and Ear Infirmary of Mount Sinai who specialize in Dermatology. He has more than 100 publications and over 500 citings.

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiResidency, Dermatology, 1981 - 1983
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1978 - 1981
  • Harvard Medical School
    Harvard Medical SchoolClass of 1978

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1980 - 2025
  • American Board of Dermatology Dermatology
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Gold Medal American Academy of Dermatology, 2022
  • Top MD Consumers Checkbook
  • Whos Who in Medicine and Healthcare Marquis Whos Who
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Dilemmas and Challenges in Skin Cancer Therapies and Management 
    American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019

Press Mentions

  • Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
    Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-to-Severe Scalp Psoriasis and in a Real-World SettingSeptember 27th, 2024
  • Brodalumab: 4-Year US Pharmacovigilance Report
    Brodalumab: 4-Year US Pharmacovigilance ReportMarch 14th, 2023
  • Psoriasis Drugs for Patients with Cancer, Obesity, Psoriatic Arthritis
    Psoriasis Drugs for Patients with Cancer, Obesity, Psoriatic ArthritisFebruary 18th, 2023
  • Join now to see all

Professional Memberships